吉非贝齐与安慰剂和氯贝丁酯治疗高脂蛋白血症的比较。

The treatment of hyperlipoproteinaemia with gemfibrozil compared with placebo and clofibrate.

作者信息

Nye E R, Sutherland W H, Temple W a

出版信息

N Z Med J. 1980 Nov 12;92(671):345-9.

Abstract

In a single-blind study the lipid-lowering drug gemfibrozil was compared at fixed dosage of 1600 mg daily with placebo and other drugs (mainly clofibrate) over a nine month period in 33 patients with hyperlipidaemia. Two patients were withdrawn from the study because of gastrointestinal symptoms attributable to gemfibrozil. The drug significantly lowered plasma cholesterol and triglycerides compared to the placebo. The drug also significantly lowered plasma cholesterol and triglycerides compared to the placebo. The drug also significantly lowered very low density lipoprotein (VLDL) triglycerides and raised high density lipoprotein (HDL) cholesterol levels but a previously significant inverse relationship between VLDL triglyceride and HDL cholesterol on placebo disappeared with gemfibrozil treatment.

摘要

在一项单盲研究中，将降血脂药物吉非贝齐以每日1600毫克的固定剂量与安慰剂及其他药物（主要是氯贝丁酯），对33名高脂血症患者进行了为期九个月的比较。两名患者因吉非贝齐所致的胃肠道症状退出研究。与安慰剂相比，该药物显著降低了血浆胆固醇和甘油三酯水平。与安慰剂相比，该药物还显著降低了血浆胆固醇和甘油三酯水平。该药物还显著降低了极低密度脂蛋白（VLDL）甘油三酯水平，并提高了高密度脂蛋白（HDL）胆固醇水平，但在安慰剂组中，VLDL甘油三酯与HDL胆固醇之间先前存在的显著负相关关系在吉非贝齐治疗后消失。